BC
MRTX

Broadfin Capital’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Broadfin Capital’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-200,000
Closed -$15.6M – 49
2019
Q3 		$15.6M Hold
200,000
– – 2.88% 9
2019
Q2 		$20.6M Buy
+200,000
New +$15.6M 4.48% 6

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Broadfin Capital's MRTX Position: Q2 2019 in Review

Broadfin Capital sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2019, closing a stake of 148,100 shares — an estimated $11.5M sold.

Broadfin Capital first reported a position in MRTX in Q4 2013 and held it in 22 quarters. The position peaked at $50.3M in Q2 2018. 172 funds tracked by Wall St. Rank hold MRTX as of Q2 2019.

  • Broadfin Capital reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Broadfin Capital sold 148,100 Mirati Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $11.5M.
  • Broadfin Capital first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2013 and held it in 22 quarters.
  • Broadfin Capital's Mirati Therapeutics, Inc. Common Stock position peaked at $50.3M in Q2 2018.
  • 172 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2019.

Based on Broadfin Capital's 13F filing for Q2 2019, filed 14 Aug 2019.